Novartis Ag (NVSEF) Net Margin (2009 - 2025)

Novartis Ag has disclosed Net Margin across 14 years of filings, most recently posting 32.24% for Q2 2025.

• Net Margin for Q2 2025 came in at 32.24%, up 154.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 15.72% (up 652.0% YoY), and the FY2025 annual result was 25.64%, up 191.0% from the prior year.
• Net Margin came in at 32.24% for Q2 2025 at Novartis Ag, up from 28.63% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 284.07% in Q3 2021 to a low of 0.4% in Q2 2023.
• The 5-year median for Net Margin is 31.47% (2024), against an average of 76.11%.
• Peak annual rise in Net Margin reached 10175 bps in 2021, while the deepest fall reached 200503 bps in 2021.
• Novartis Ag's Net Margin stood at 23.48% in 2021, then soared by 153 bps to 59.45% in 2022, then tumbled by 99 bps to 0.85% in 2023, then soared by 3251 bps to 28.63% in 2024, then advanced by 13 bps to 32.24% in 2025.
• The last three Net Margin figures came in at 32.24% (Q2 2025), 28.63% (Q4 2024), and 30.7% (Q2 2024), per Business Quant data.